



August 10, 2026

To

BSE Limited

The Corporate Relationship Dept.

P.J. Towers, Dalal Street

Mumbai-400 001

Scrip Code: 500214

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block- G,

Bandra Kurla Complex, Bandra (East),

Mumbai-400 051

Symbol: IONEXCHANG

Sub.: Submission of Earnings Presentation – Q1 FY 2026-27

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation being made to the Investors and Analysts (Group Meet) to discuss the financial performance of the Company for the first quarter ended June 30, 2026.

The aforesaid information is also available on the website of the Company and can be accessed at www.ionexchangeglobal.com.

Kindly take the information on record.

Thanking You,

Yours faithfully,

For Ion Exchange (India) Limited

Nikisha Solanki

Company Secretary & Compliance Officer

ACS- 50894

Encl.: As stated above



Earnings Presentation

Q1-FY27

Company Snapshot



62 +
YEARS OF
EXPERTISE

OPERATIONS IN
50 +
COUNTRIES



360° TOTAL WATER &
ENVIRONMENT MANAGEMENT



WORLD CLASS
MANUFACTURING FACILITIES



ONE OF ASIA'S LARGEST
SERVICE NETWORKS



EXPORTS ACROSS
CONTINENTS



SERVING
INDUSTRIES,
INSTITUTIONS,
HOMES &
COMMUNITIES



GLOBAL ASSEMBLY HUBS IN
UAE, SAUDI ARABIA, SOUTH
AFRICA, INDONESIA &
BANGLADESH



ADVANCED R&D
CENTRES IN INDIA



COMMITTED TO
SUSTAINABILITY

200,000 +
INSTALLATIONS WORLD-WIDE



3,000 +
CORE INDUSTRY PROJECTS

Total Water & Environment Management Solutions



Capabilities

Leaders in Resins, Membranes & Chemicals, with a Unique End-to-End Portfolio
Spanning Solutions, Digital & Services



Global Presence



50+

COUNTRIES SERVED

30%

INTERNATIONAL
REVENUE SHARE

14

GLOBAL MANUFACTURING FACILITIES
& ASSEMBLY CENTRES

200,000+

GLOBAL
INSTALLATIONS

Our Global Offices

Global Manufacturing Facilities



Ankleshwar, Gujarat
Resins Manufacturing - Exports



Roha, Maharashtra
Non-Solvent Resins



Verna, Goa
Centre of Membrane Excellence



Patancheru, Telangana
Chemicals Manufacturing



Saudi Arabia
Chemical Blending Facility



Portugal
MAPRIL, Manufacturing Facility

Global Manufacturing Facilities



Hosur, Tamil Nadu
Standard Systems Assembly



Verna, Goa
Standard Membrane Systems



Wada, Maharashtra
Standard Systems Assembly



Palaspe, Maharashtra
Large System Assembly



UAE
Assembly Unit, ICV Certified Facility



South Africa
Manufacturing Facility




Indonesia
Assembly and Testing Center



Bangladesh
Fabrication Unit & Assembly Centre

Current vs New Reporting Segments

Ion Exchange (India) Ltd.



New Reporting Segments

TREATMENT SOLUTIONS



- **Water Treatment**
- **Ultra Pure Water**
- **High Purity Water**
- **Desalination**
- **Wastewater Treatment & Recycle**
- **Zero Liquid Discharge (ZLD)**
- **PFAS**

INDUSTRIAL PRODUCTS



- **Standard Water Treatment Solutions**
- **Membranes (RO, UF, NF, MBR)**
- **Institutional Water Treatment Products**

LIFECYCLE SERVICES



- **Operations & Maintenance (O&M)**
- **Rehabilitation & Modification**
- **Spares, Services & Consumables**
- **BOO/BOOT/WaaS**
- **Rentals**
- **Audits**
- **Remote Monitoring**

SPECIALTY CHEMICALS



- **Water Treatment Chemicals**
 - Utility Chemicals
 - Process Chemicals
 - Membrane Chemicals
 - Polymers
- **Resins**
 - Industrial
 - Process
 - Pharma

CONSUMER PRODUCTS



- **Home Water Solutions**
- **Community Water Treatment Solutions**
- **Wellness**
 - Hydrogen Water
 - Alkaline Water



Financial Overview

Q1-FY27



Q1-FY27 Financial Highlights

Q1-FY27 Performance (Standalone)

INR 6,356 Mn
Operating Income

INR 307 Mn
Operating EBITDA

4.83 %
Operating EBITDA
Margins

INR 114 Mn
Net Profit

1.79 %
PAT Margins

INR 0.93 /Share
Diluted EPS

Q1-FY27 Performance (Consolidated)

INR 7,005 Mn
Operating Income

INR 318 Mn
Operating EBITDA

4.54 %
Operating EBITDA
Margins

INR 31 Mn
Net Profit

0.44 %
PAT Margins

INR 0.35 /Share
Diluted EPS

Order Book and Pipeline (As on 30 June, 2026) for Treatment Solutions, Industrial Products & Lifecycle Services

Engineering projects[^]
~ INR 21,820 Mn

Outstanding Sri Lanka
~ INR 100 Mn

Outstanding UP SWSM
~ INR 2,810 Mn


Total Orderbook
~ INR 24,730 Mn

Bid Pipeline
~ INR 97,770 Mn

[^]Excluding Sri Lanka Order, UP SWSM. and the recent Contract awarded to the Co – USD 52.83 Mn by Hyundai Engineering & Construction

Quarterly Consolidated Segmental Breakup

Treatment Solutions



Q1-FY27 Performance Highlights


- Revenue growth of 14%
- GCC Dispatches resumed .. To pick up momentum
- Margins continue to be impacted by legacy projects

Future Growth Drivers

- Existing backlog liquidation
- New emerging segments
- Overseas opportunities

Quarterly Consolidated Segmental Breakup

Industrial Products



Q1-FY27 Performance Highlights


- Revenue growth of 14%
- EBIT% up from 5.53% to 11.89%
- Strong performance by Standard Water Treatment Solutions and Membranes

Future Growth Drivers

- Manufacturing expansion for UF Membranes
- Expanded capacity for Standard Plants & Systems
- Increasing overseas geographical reach

Quarterly Consolidated Segmental Breakup

Lifecycle Services



Q1-FY27 Performance Highlights


- Revenue growth of 28%
- EBIT% down from 10.55% to 9.92% due to input costs
- Focus on O&M and Consumables

Future Growth Drivers

- Expanding solution offerings
- Retrofit business and BOO/BOOT
- Digital portfolio and solutions

Quarterly Consolidated Segmental Breakup

Specialty Chemicals



Q1-FY27 Performance Highlights


- Revenue growth of 21%
- EBIT down to 9.71% due to geopolitical impact
- Higher costs due to Roha facility capex

Future Growth Drivers

- Increased offtake from Roha Plant
- Pharma Resins
- Higher share in process chemicals

Quarterly Consolidated Segmental Breakup

Consumer Products



Q1-FY27 Performance Highlights

- Revenue Growth of 33%
- EBIT slightly up from -0.59% to -0.27%
- Strong growth across all key product lines

Future Growth Drivers

- Growth in the Softener market
- Wellness product offerings
- New products like OTG

Quarterly Consolidated Financial Performance

INCOME STATEMENT (INR Mn)	Q1-FY27	Q1-FY26	Y-o-Y	Q4-FY26	Q-o-Q
Operating Income	7,005	5,832	20.1%	8,633	(18.9)%
Expenses	6,687	5,205	28.5%	8,434	(20.7)%
Operating EBITDA	318	627	(49.3)%	199	59.8%
Operating EBITDA Margins (%)	4.54%	10.75%	(622) bps	2.31%	223 bps
Depreciation	218	123	77.2%	196	11.2%
Finance Cost	90	26	NA	108	(16.7)%
Other Income	60	177	NA	430	NA
PBT before Exceptional Items	70	655	(89.3)%	325	(78.5)%
Exceptional Items	-	-	NA	(1)	NA
PBT	70	655	(89.3)%	326	(78.5)%
Share of Profit of equity accounted Investee	4	4	NA	(1)	NA
Tax	43	175	(75.4)%	82	(47.6)%
Profit After Tax	31	484	(93.6)%	243	(87.2)%
PAT Margins (%)	0.44%	8.30%	(786) bps	2.81%	(237) Bps
Other Comprehensive Income	3	21	(85.7)%	15	(80.0)%
Total Comprehensive Income	34	505	(93.3)%	258	(86.8)%
Diluted EPS (INR)#	0.347	4.108	(91.6)%	2.036	(83.0)%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)

Quarterly Standalone Financial Performance

INCOME STATEMENT (INR Mn)	Q1-FY27	Q1-FY26	Y-o-Y	Q4-FY26	Q-o-Q
Operating Income	6,356	5,178	22.8%	8,139	(21.9)%
Expenses	6,049	4,616	31.0%	8,028	(24.7)%
Operating EBITDA	307	562	(45.4)%	111	176.6%
Operating EBITDA Margins (%)	4.83%	10.85%	(602) bps	1.36%	347 bps
Depreciation	203	110	84.5%	184	10.3%
Finance Cost	82	17	382.4%	101	(18.8)%
Other Income	132	195	NA	447	NA
PBT before Exceptional Items	154	630	(75.6)%	273	(43.6)%
Exceptional Items	-	-	NA	-	NA
PBT	154	630	(75.6)%	273	(43.6)%
Tax	40	161	(75.2)%	77	(48.1)%
Profit After Tax	114	469	(75.7)%	196	(41.8)%
PAT Margins (%)	1.79%	9.06%	(727) bps	2.41%	(62) bps
Other Comprehensive Income	(1)	-	NA	(6)	NA
Total Comprehensive Income	113	469	(75.9)%	190	(40.5)%
Diluted EPS (INR)#	0.927	3.814	(75.7)%	1.592	(41.8)%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)



Historic Financial Overview

Historical Standalone Financial Performance

INCOME STATEMENT (INR Mn)	FY23	FY24	FY25	FY26	Q1-FY27
Operating Income	18,923	21,800	25,401	26,789	6,356
Expenses	16,544	19,129	22,549	24,946	6,049
Operating EBITDA	2,379	2,671	2,852	1,843	307
Operating EBITDA Margins (%)	12.57%	12.25%	11.23%	6.88%	4.83%
Depreciation	281	330	400	576	203
Finance Cost	90	67	84	205	82
Other Income	450	470	512	950	132
PBT before Exceptional Items	2,458	2,744	2,880	2,012	154
Exceptional Items	-	-	-	145	-
PBT	2,458	2,744	2,880	1,867	154
Tax	607	703	735	483	40
Profit After Tax	1,851	2,041	2,145	1,384	114
PAT Margins (%)	9.78%	9.36%	8.44%	5.17%	1.79%
Other Comprehensive Income	(23)	(9)	(1)	(6)	(1)
Total Comprehensive Income	1,828	2,032	2,144	1,378	113
Diluted EPS (INR) @	15.060	16.603	17.447	11.257	0.927

@Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)

Historical Standalone Balance Sheet

PARTICULARS (INR Mn)	FY24	FY25	FY26
EQUITIES & LIABILITIES			
Equity			
(A) Equity Share Capital	147	147	147
(B) Other Equity	10,597	12,556	13,750
Total Equity	10,744	12,703	13,897
Non-Current Liabilities			
(A) Financial Liabilities			
(i) Borrowings	438	1,980	3,082
(ii) Lease Liabilities	87	125	160
(iii) Other financial Liabilities	146	134	124
(B) Provisions	231	173	263
Total Non – Current Liabilities	902	2,412	3,629
Current Liabilities			
(A) Financial Liabilities			
(i) Borrowings	34	290	760
(ii) Lease Liabilities	33	46	97
(iii) Trade Payables	6,508	7,346	8,468
(iv) Other Financial Liabilities	589	891	817
(B) Other Current Liabilities	4,383	5,071	4,644
(C) Provisions	72	68	223
(D) Liabilities for current tax (Net)	43	87	69
Total Current Liabilities	11,662	13,799	15,078
GRAND TOTAL - EQUITIES & LIABILITIES	23,308	28,914	32,604

PARTICULARS (INR Mn)	FY24	FY25	FY26
ASSETS			
Non-Current Assets			
(A) Property, Plant and Equipment	2,149	2,414	5,851
(B) Capital Work-in-progress	607	3,170	1,747
(C) Right-of-Use Assets	357	374	428
(D) Other Intangible Assets	125	165	91
(E) Financial Assets			
(i) Investments	842	855	869
(ii) Trade Receivables	9	7	3
(iii) Loans	220	618	566
(iv) Other Financial Assets	87	91	119
(F) Other Non-Current Assets	242	469	377
(G) Deferred Tax Assets	78	73	140
Total Non – Current Assets	4,716	8,236	10,191
Current Assets			
(A) Inventories	1,887	2,410	3,856
(B) Financial Assets			
(i) Investments	5	4	6
(ii) Trade Receivables	9,217	10,988	10,725
(iii) Cash & Cash Equivalents	1,104	1,158	1,411
(iv) Bank Balances	4,246	3,086	1,300
(v) Loans	408	122	99
(vi) Other Financial Assets	142	108	54
(C) Other current assets	1,583	2,802	4,962
Total Current Assets	18,592	20,678	22,413
GRAND TOTAL – ASSETS	23,308	28,914	32,604

Historical Consolidated Financial Performance

INCOME STATEMENT (INR Mn)	FY23	FY24	FY25	FY26	Q1-FY27
Operating Income	19,896	23,479	27,371	29,148	7,005
Expenses	17,346	20,759	24,432	27,046	6,687
Operating EBITDA	2,550	2,720	2,939	2,102	318
Operating EBITDA Margins (%)	12.82%	11.58%	10.74%	7.21%	4.54%
Depreciation	291	364	445	626	218
Finance Cost	92	121	135	240	90
Other Income	411	439	486	865	60
PBT before Exceptional Items	2,578	2,674	2,845	2,101	70
Exceptional Items	-	-	-	169	-
PBT	2,578	2,674	2,845	1,932	70
Share of Profit of equity accounted Investee	9	15	10	17	4
Tax	637	735	772	517	43
Profit After Tax	1,950	1,954	2,083	1,432	31
PAT Margins (%)	9.80%	8.32%	7.61%	4.91%	0.44%
Other Comprehensive Income	(17)	(3)	1	70	3
Total Comprehensive Income	1,933	1,951	2,084	1,502	34
EPS Diluted (INR) @	16.595	16.534	17.530	12.034	0.347

@Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No. of Shares- 43,78,740)


Historical Consolidated Balance Sheet

PARTICULARS (INR Mn)	FY24	FY25	FY26
EQUITIES & LIABILITIES			
Equity			
(A) Equity Share Capital	142	142	142
(B) Other Equity	10,037	11,937	13,248
Equity attributable to owners	10,179	12,079	13,390
Non Controlling Interest	19	16	13
Total Equity	10,198	12,095	13,403
Non-Current Liabilities			
(A) Financial Liabilities			
(i) Borrowings	1,091	2,521	3,576
(ii) Lease liabilities	110	143	171
(iii) Other Financial Liabilities	146	133	125
(B) Provisions	261	208	302
(C) Deferred Tax Liabilities (Net)	93	88	88
(D) Other Non-Current Liabilities	4	-	-
Total Non – Current Liabilities	1,705	3,093	4,262
Current Liabilities			
(A) Financial Liabilities			
(i) Borrowings	285	510	968
(ii) Lease liabilities	38	53	107
(iii) Trade Payables	6,946	7,790	8,997
(iv) Other Financial Liabilities	633	944	880
(B) Other Current Liabilities	4,545	5,199	4,817
(C) Provisions	84	78	280
(D) Liabilities for current tax (Net)	60	107	85
Total Current Liabilities	12,591	14,681	16,134
GRAND TOTAL - EQUITIES & LIABILITES	24,494	29,869	33,799

PARTICULARS (INR Mn)	FY24	FY25	FY26
ASSETS			
Non-Current Assets			
(A) Property, Plant and Equipment	3,018	3,280	6,853
(B) Capital Work-in-progress	607	3,178	1,747
(C) Right-of-Use Assets	383	394	444
(D) Other Intangible Assets	162	203	140
(E) Goodwill	102	102	102
(F) Investment accounted using Equity Method	62	68	85
(G) Financial Assets			
(i) Investments	55	59	68
(ii) Trade Receivables	42	7	3
(iii) Other Financial Assets	158	154	175
(H) Deferred Tax Assets (Net)	85	77	144
(I) Other Non-Current Assets	308	536	445
(J) Non-Current Tax Assets	6	8	26
Total Non – Current Assets	4,988	8,066	10,232
Current Assets			
(A) Inventories	2,365	2,990	4,414
(B) Financial Assets			
(i) Investments	5	4	6
(ii) Trade Receivables	9,348	11,074	10,747
(iii) Cash & Cash Equivalents	1,536	1,493	1,846
(iv) Bank Balances	4,343	3,165	1,341
(v) Loans	79	53	66
(vi) Other Financial Assets	160	133	79
(C) Current Tax Assets (Net)	11	5	22
(D) Other Current Assets	1,659	2,886	5,046
Total Current Assets	19,506	21,803	23,567
GRAND TOTAL – ASSETS	24,494	29,869	33,799

Consolidated Historical Financial Performance

Revenues (INR Mn)



Summary


- Growth till FY25 driven by strong backlog
- FY26 growth impacted by geopolitical challenges
- Chemicals and CPD Segments growing strongly

Future Actions

- Treatment Solutions growth from overseas backlog
- Specialty Segment growth from Roha Plant
- Continued growth in Consumer Products

Consolidated Historical Financial Performance

Operating EBITDA (INR Mn)



Summary


- Impact of Higher Cost profile in certain EPC contracts
- Slowed execution of UP Contract
- Roha Facility Costs consequent to plant commissioning in FY 26
- Impact of West Asia crisis
- Investment in overseas Geographies

Future Actions

- Strengthening presence in International Markets
- Ramp up of Roha volumes
- Growth in Industrial Products and Lifecycle Services
- Profitability of Consumer Products

Consolidated Historical Financial Performance

PAT (INR Mn)



Summary


- Impact of Higher Cost profile in certain EPC contracts
- Slowed execution of UP Contract
- Roha Facility Costs consequent to plant commissioning in FY 26
- Impact of West Asia crisis

Future Actions

- Strengthening presence in International Markets
- Ramp up of Roha volumes
- Growth in Industrial Products and Lifecycle Services
- Profitability of Consumer Products

Consolidated Historical Financial Performance

Net Debt / Equity



Summary


- Ratio within acceptable levels
- Roha Capex financed by term loan
- Lower Operating EBIDTA in FY 25 and FY 26

Future Actions

- Revenue generation from Roha facility
- Higher share of Industrial Products, Life cycle Services and Specialty Chemicals
- Continue disciplined Capital Allocation

Consolidated Historical Financial Performance

Return Ratios



Summary


- Roha Plant Capex impact
- West Asia crisis impacted gross working capital
- Reduced Profitability

Future Actions

- Higher share of Industrial Products, Life cycle Services and Specialty Chemicals
- Continue disciplined Capital Allocation

Consolidated Historical Financial Performance

Working Capital Days



Summary


- High proportion in Treatment Solution segment
- Impact of West Asia crisis in FY 26

Future Actions

- Increased business from Industrial Products, Lifecycle Services and Specialty Chemicals
- Increased share of International business
- Focus on improving Working Capital Cycle

Market Data (Bloomberg – ION IN, Reuters – IONX.BO)


1 YEAR SHARE PRICE MOVEMENT (UP TO 30th June 2026)



PRICE DATA (As on 30th June 2026)

Face value (INR)	1.00
Market Price (INR)	408.40
52 Week H/L (INR)	580.65 / 312.30
Market Cap (INR Mn)	59,898.64
Equity Shares Outstanding (Mn)	146.67
1 Year Avg. trading volume ('000)	338.50

SHAREHOLDING PATTERN (As on 30th June 2026)



Disclaimer

Ion Exchange (India) Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited ("Company " or "IONEX "), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



VALOREM ADVISORS

For further details please contact our Investor Relations Representatives:

VALOREM ADVISORS

Mr. Anuj Sonpal

Tel: +91-22-35075100

Email: ion@valoremadvisors.com

Investor kit link: <https://valoremadvisors.com/ion>



www.ionexchangeglobal.com






Annexures

Quarterly Standalone Segmental Breakup

Treatment Solutions



Q1-FY27 Performance Highlights


- Revenue Growth of 16%
- Dispatches to GCC resumed .. Pick up going forward
- Margins continue to be impacted by few legacy projects

Future Growth Drivers

- Existing backlog liquidation
- New emerging segments
- Overseas Opportunities

Quarterly Standalone Segmental Breakup

Industrial Products



Q1-FY27 Performance Highlights


- Revenue Growth of 19%
- EBIT% up from 5.20% to 12.99%
- Strong performance by Standard Water Treatment Solutions and Membranes

Future Growth Drivers

- Manufacturing expansion for UF Membranes
- Expanded capacity for Standard Plants & Systems
- Increasing overseas geographical reach

Quarterly Standalone Segmental Breakup

Lifecycle Services



Q1-FY27 Performance Highlights


- Revenue Growth of 25%
- EBIT% increase from 8.55% to 10.56%
- Focus on O&M and Consumables

Future Growth Drivers

- Expanding solution offerings
- Retrofit business and BOO/BOOT
- Digital portfolio and solutions

Quarterly Standalone Segmental Breakup

Specialty Chemicals



Q1-FY27 Performance Highlights


- Revenue Growth of 27%
- EBIT down from 27.94% to 13.33% due to geopolitical impact
- Higher depreciation costs due to Roha facility capex

Future Growth Drivers

- Increased offtake from Roha Plant
- Pharma Resins
- Higher share in process chemicals

Quarterly Standalone Segmental Breakup

Consumer Products



Q1-FY27 Performance Highlights

- Revenue Growth of 33%
- EBIT slightly up from -0.71% to -0.36%
- Strong growth across all key product lines

Future Growth Drivers

- Softener growth
- Wellness product offerings
- New products like OTG